These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8653684)

  • 41. [Familial malignant melanoma].
    Ueda M
    Nihon Rinsho; 2000 Jul; 58(7):1381-4. PubMed ID: 10921309
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma.
    Zuo L; Weger J; Yang Q; Goldstein AM; Tucker MA; Walker GJ; Hayward N; Dracopoli NC
    Nat Genet; 1996 Jan; 12(1):97-9. PubMed ID: 8528263
    [No Abstract]   [Full Text] [Related]  

  • 43. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.
    FitzGerald MG; Harkin DP; Silva-Arrieta S; MacDonald DJ; Lucchina LC; Unsal H; O'Neill E; Koh J; Finkelstein DM; Isselbacher KJ; Sober AJ; Haber DA
    Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8541-5. PubMed ID: 8710906
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CDKN2 explains part of the clinical phenotype in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families.
    Gruis NA; Sandkuijl LA; van der Velden PA; Bergman W; Frants RR
    Melanoma Res; 1995 Jun; 5(3):169-77. PubMed ID: 7640518
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Melanoma development in relation to non-functional p16/INK4A protein and dysplastic naevus syndrome in Swedish melanoma kindreds.
    Hashemi J; Linder S; Platz A; Hansson J
    Melanoma Res; 1999 Feb; 9(1):21-30. PubMed ID: 10338331
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mutational analysis of the CDKN2 gene in metastases from patients with cutaneous malignant melanoma.
    Platz A; Ringborg U; Lagerlöf B; Lundqvist E; Sevigny P; Inganäs M
    Br J Cancer; 1996 Feb; 73(3):344-8. PubMed ID: 8562340
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Constitutional alterations in p16 in patients with uveal melanoma.
    Wang X; Egan KM; Gragoudas ES; Kelsey KT
    Melanoma Res; 1996 Dec; 6(6):405-10. PubMed ID: 9013477
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of p16 gene deletion and point mutation in breast carcinoma.
    Quesnel B; Fenaux P; Philippe N; Fournier J; Bonneterre J; Preudhomme C; Peyrat JP
    Br J Cancer; 1995 Aug; 72(2):351-3. PubMed ID: 7640217
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.
    Parry D; Peters G
    Mol Cell Biol; 1996 Jul; 16(7):3844-52. PubMed ID: 8668202
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Familial melanoma and p16--a hung jury.
    Wainwright B
    Nat Genet; 1994 Sep; 8(1):3-5. PubMed ID: 7987389
    [No Abstract]   [Full Text] [Related]  

  • 51. Link to hereditary melanoma brightens mood for p16 gene.
    Marx J
    Science; 1994 Sep; 265(5177):1364-5. PubMed ID: 8073268
    [No Abstract]   [Full Text] [Related]  

  • 52. The current situation with regard to human melanoma and genetic inferences.
    Hayward NK
    Curr Opin Oncol; 1996 Mar; 8(2):136-42. PubMed ID: 8727306
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Germline mutations of the CDKN2 gene in UK melanoma families.
    Harland M; Meloni R; Gruis N; Pinney E; Brookes S; Spurr NK; Frischauf AM; Bataille V; Peters G; Cuzick J; Selby P; Bishop DT; Bishop JN
    Hum Mol Genet; 1997 Nov; 6(12):2061-7. PubMed ID: 9328469
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Frequent allelic losses of 9p21 markers and low incidence of mutations at p16(CDKN2) gene in non-Hodgkin lymphomas of B-cell lineage.
    Fernández-Piqueras J; Santos J; Pérez de Castro I; Meléndez B; Martínez B; Robledo M; Rivas C; Benítez J
    Cancer Genet Cytogenet; 1997 Oct; 98(1):63-8. PubMed ID: 9309120
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Involvement of the p16INK4 (CDKN2) gene in familial melanoma.
    Naylor MF; Everett MA
    Melanoma Res; 1996 Apr; 6(2):139-45. PubMed ID: 8791272
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Familial uveal melanoma: absence of germline mutations involving the cyclin-dependent kinase-4 inhibitor gene (p16).
    Singh AD; Croce CM; Wary KK; Shields JA; Donoso LA; Shields CL; Huebner K; Ohta M
    Ophthalmic Genet; 1996 Mar; 17(1):39-40. PubMed ID: 8740697
    [No Abstract]   [Full Text] [Related]  

  • 57. Sunlight and melanoma: an answer from MTS1 (p16).
    Maestro R; Boiocchi M
    Science; 1995 Jan; 267(5194):15-6. PubMed ID: 7809600
    [No Abstract]   [Full Text] [Related]  

  • 58. Genes involved in cell cycle G1 checkpoint control are frequently mutated in human melanoma metastases.
    Platz A; Sevigny P; Norberg T; Ring P; Lagerlöf B; Ringborg U
    Br J Cancer; 1996 Sep; 74(6):936-41. PubMed ID: 8826861
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Familial melanoma-associated mutations in p16 uncouple its tumor-suppressor functions.
    Jenkins NC; Jung J; Liu T; Wilde M; Holmen SL; Grossman D
    J Invest Dermatol; 2013 Apr; 133(4):1043-51. PubMed ID: 23190892
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The CDKN2A (p16) gene and human cancer.
    Foulkes WD; Flanders TY; Pollock PM; Hayward NK
    Mol Med; 1997 Jan; 3(1):5-20. PubMed ID: 9132280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.